| Phase 17 trials |
|
Phase 1
|
NCT03783897 |
Nov 2018 → Jun 2019 |
metabolic dysfunction-associated steatohepatitis |
Enanta Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03748628 |
Oct 2018 |
metabolic dysfunction-associated steatohepatitis |
Enanta Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03610945 |
Jul → Aug 2018 |
metabolic dysfunction-associated steatohepatitis |
Enanta Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03213145 |
Jul → Aug 2017 |
metabolic dysfunction-associated steatohepatitis |
Enanta Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03207425 |
Jun → Sep 2017 |
metabolic dysfunction-associated steatohepatitis |
Enanta Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03187496 |
May → Jun 2017 |
metabolic dysfunction-associated steatohepatitis |
Enanta Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02918929 |
Sep 2016 → Jun 2017 |
fatty liver disease |
Enanta Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
| Phase 23 trials |
|
Phase 2
|
NCT04378010 |
Jan 2020 → Oct 2021 |
metabolic dysfunction-associated steatohepatitis |
Enanta Pharmaceuticals, Inc |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT03421431 |
Apr 2018 → Jun 2019 |
metabolic dysfunction-associated steatohepatitis |
Enanta Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03394924 |
Dec 2017 → Dec 2019 |
primary biliary cholangitis |
Enanta Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|